Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice

AIDS

Volumn 12, Issue 8, 1998, Pages 865-872

  Del Real, Gustavo ^a   Llorente, Mercedes ^a   Boscá, Lisardo ^b   Hortelano, Sonsoles ^b   Serrano, Antonio ^a   Lucas, Pilar ^a   Gómez, Lucio ^a   Torán, Jose L ^a   Redondo, Clara ^c   Martínez A, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Instituto de Bioquimica   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

AIDS; Cytokines; HIV 1; Linomide

Indexed keywords

CD4 ANTIGEN; IMMUNOMODULATING AGENT; ROQUINIMEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SCID MOUSE; SPLEEN; T LYMPHOCYTE; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYQUINOLINES; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PERITONEAL CAVITY; SPLEEN; VIRAL LOAD; VIRUS REPLICATION;

EID: 7144254458     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199808000-00008     Document Type: Article

References (35)

1. Johnson C, Tufveson G: The immunomodulator LS-2616 (linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation. Transplant Immunol 1994, 2:56-60.
2. Kalland T: Effects of the immunomodulator LS2616 on growth and metastasis of the murine melanoma. Cancer Res 1986, 446:3018-3023.
3. Gonzalo JA, Gonzalez-García A, Kalland T, Hedlund C, Martínez C, Kroemer G: Linomide, a novel immunomodulator that prevents death in four models of septic shock, Eur J Immunol 1993, 23:2372-2376.
4. Hortelano S, Diaz-Guerra MJM, Gonzalez-García A, et al.: Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-Ipr Ipr mice. J Immunol 1997, 158:1402-1408.
5. Arad G, Katzenellenbogen M, Levy R, Slavi S, Kaempfer R: Linomide, an immunomodulator that inhibits Th1 cytokine gene expression, Int Immunol 1996, 8:1603-1607.
6. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlund G, Martinez-A C, Kroerner G: Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 1994, 24:48-53.
7. Condiotti R, Slavin S, Barak V, Nagler A: The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Leukemia Res 1996, 11:57-63.
8. Natham C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992, 66:3051-3064.
9. Hibhs J: Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 1991, 142:565-570.
10. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
11. Natham C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem 1994, 269:13725-13728.
12. Xie QW, Whisnant R, Natham C: Promotor of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility of interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993, 177:1779-1784.
13. Bukrinsky MI, Nottet HSLM, Schmidtmayerova H, et al.: Regulation of nitric oxide synthase activity in human immunodeficiency type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med 1995, 181:735-745.
14. Merrill JE, Koyanagi Y, Zack J, Thomas L, Martin F, Chen IS: Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 1992, 66:2217-2225.
15. Koka P, He K, Zack JA, et al: Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal and adult human brain. J Exp Med 1995, 182:941-951.
16. Dulbecco R: End-point method. Measurement of the infectious titer of a viral sample. In Virology. 2nd Edn. Edited by Dulbecco R, Ginsberg HS. Philadelphia: JP Lippincott: 1988:22-25.
17. Koup RA, Ho DD: Quantitative culture assay for HIV-1 in peripheral blood. In Techniques in HIV Research. Edited by Aldovini A, Walker BD. New York: Stockton Press; 1990:107-112.
18. Redondo C, Flores I, Gonzalez A, et al.: Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invent 1996, 98:1245-1252.
19. Mosier DE: Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice. Adv Immunol 1996, 63:79-125.
20. Kollmann TR, Pettoello-Mantovani M, Zhuang X, et al.: Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. J Exp Med 1994, 179:513-522.
21. Maury CPJ, Teppo AM, Repo H, Lahdevirta J: Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988, 85:289-291.
22. Rosenberg ZF, Fauci AS: Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression, Immunol Today 1990, 11:176-180.
23. Poli G, Fauci AS: Cytokine modulation of HIV expression. Semin Immunol 1993, 5:165-173.
24. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
25. Ho DD: Viral counts in HIV infection. Science 1996, 272:1124-1125.
26. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
27. Clerici M, Piconi S, Balotta C, et al.: Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viraemia in asymptomatic HIV-seropositive persons. J Infect Dis 1997, 175:1210-1215.
28. Kollmann TR, Pettoello-Mantovani M, Katopodis NF, et al.: Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc Natl Acad Sci USA 1996, 93:3126-3131.
29. Mollace VM, Colasanti T, Persichini G, Bagetta G, Lauro GM, Nistico G: HIV-1 gp120 glycoprotein stimulates the inducible isoform of NO synthase in human cultured astrocytoma cells. Biochem Biophys Res Commun 1993, 194:439-445.
30. Pietraforte D, Tritarelli E, Testa V, Minetti M: gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocytederived macrophages. J Leukoc Biol 1994, 55:175-182.
31. Adamson DC, Wildemann B, Sasaki M, et al.: Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996, 274:1917-1921.
32. McCune JM, Namikawa R, Shih C, Rabin L, Kaneshima H: Suppression of HIV-1 infection in AZT-treated SCID-hu mice. Science 1990, 247:564-566.
33. Pettoello-Mantovani M, Kollmann TR, Raker C, et al.: Saquinavir-mediated inhibition of human immunodeficiency virs (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues. Antimicrob Agents Chemother 1947, 41:1880-1887.
34. Bengston M, Simmonson B, Carlsson K, et al.: Stimulation of NK cell, T-cell and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992, 53:882-888.
35. Karussis DM, Slavis S, Lehman D, et al.: Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis with linomide (LS-2616) a synthetic immunomodulator. Proc Natl Acad Sci USA 1993, 90:6400-6404.